On this page
What it is
BPC-157 is a short chain of 15 amino acids derived from a protein naturally found in human stomach juice. Researchers isolated the fragment they believed was responsible for the stomach lining's remarkable ability to protect and repair itself, and named it "Body Protection Compound."
It is not an approved drug anywhere in the world. In the research-peptide market it is sold as a material for laboratory study only. Almost everything known about it comes from cell and rodent experiments — there are, as of 2026, essentially no large, controlled human trials.
What people research it for
Faster tendon & ligament recovery
Animal studiesIn rats, BPC-157 accelerated healing of transected Achilles tendons and improved tendon-to-bone healing. This is the most-cited reason people in the research community are interested in it.
Gut protection
Animal studiesIts original research context was the digestive tract: it protected against and helped heal stomach and intestinal ulcers in rodents, and is studied in models of inflammatory bowel disease.
Muscle and soft-tissue repair
Animal studiesRodent studies show faster healing of crushed or torn muscle. Anecdotal human reports echo this, but anecdote is not controlled evidence.
How it works
The leading theory is that BPC-157 promotes angiogenesis — the growth of new blood vessels — which brings more blood flow to an injured area and speeds repair. It appears to do this partly by boosting a growth-factor receptor pathway (VEGFR2) involved in blood-vessel formation.
Animal studies also suggest it interacts with the nitric oxide system (which controls blood-vessel dilation) and may modulate growth-factor signaling that tells cells to rebuild tissue. In plain terms: it seems to help the body's own repair crew show up faster and in greater numbers.
What the research actually shows
The BPC-157 literature is large but almost entirely preclinical — cell cultures and rodents, much of it from a single research group in Croatia. Effects on tendon, ligament, muscle, gut, and even nerve healing have been reported repeatedly in animals.
ClinicalTrials.gov record NCT07437547 describes a recruiting, randomized, placebo-controlled Phase 2 study from Hudson Biotech in 120 estimated adults ages 18 to 45 with MRI-confirmed acute grade II hamstring strain. The listed design compares subcutaneous BPC 157 with placebo once daily for 14 days alongside the same supervised rehabilitation program. As of September 29, 2026, PeptidePub does not treat this registry entry as independently validated evidence that an active trial is underway.
The credibility issue is the sponsor's registry history. Hudson Biotech also registered NCT07481734 with “(Mock Study)” in its title and protocol text, and NCT07481747 under Lilly's established SURMOUNT-1 title and acronym. The three records list the same February 2, 2026 start date, Shenzhen location, and sponsor contacts. Until the sponsor, site, and recruitment activity are independently confirmed, NCT07437547 is a registry claim, not efficacy evidence. It has no posted results.
On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend BPC-157 free base and BPC-157 acetate for inclusion on the Section 503A Bulks List. This was a non-binding advisory recommendation, not FDA approval or final placement on the list. For buyers, the practical quality checks remain the same: confirm exact BPC-157 identity, a batch-matched COA from a named lab, tested net content rather than purity alone, sterility and endotoxin results where available, and effective price per mg after discounts. Compare current offers on PeptidePub's BPC-157 price page and check vendor testing records before checkout.
That leaves BPC-157 with promising preclinical signals but no validated controlled human efficacy result. For buyers comparing vials today, the strongest move is still product proof: exact BPC-157 identity, lot-matched COA, net-content testing, named third-party lab, sterility and endotoxin checks when available, vendor transparency, and real price per mg after code before checkout.
October 2026 BPC-157 compounding policy update
On October 15, HHS and FDA sent an “Interim Access Policy for Compounding Using Certain Peptides” to the White House Office of Management and Budget for review. The public filing did not disclose the policy text or name the covered substances. CNBC reported, citing two unnamed people familiar with the plan, that it was expected to provide temporary enforcement discretion for certain peptides and specifically named BPC-157.
That report is a process update, not an active or final policy. It does not establish FDA approval, Section 503A Bulks List placement, or permission for every pharmacy to compound BPC-157. It is also separate from the July 23 advisory-panel vote, which remains a nonbinding recommendation.
What buyers should verify now
For a compounded product, ask the pharmacy for identity, concentration, sterility, endotoxin, and dispensing details. For a research vial, verify exact BPC-157 identity, an exact-lot COA, quantitative net content, the named testing lab, and sterility and endotoxin evidence where available. Then compare the current BPC-157 price per milligram, review vendor testing records, apply the PeptidePub testing methodology, and check active deals and codes.
Handling & storage
Storage at a glance
Vendor consensus- Lyophilized
- -20°C long term; 2 to 8°C for short periods
- 24+ months at -20°C is vendor guidance; no independently validated shelf life was found
- Keep sealed, dry, and dark. The often repeated refrigerated shelf life is vendor guidance, not a published BPC-157 stability study.
- Reconstituted
- 2 to 8°C
- Use within 28-30 days
- Vendor consensus for bacteriostatic-water preparations. No clinical formulation label supports this window.
- Light
- Protect from light and moisture.
- Room temperature
- Dry powder can tolerate ordinary shipping for days to weeks under general peptide guidance; avoid sustained heat and do not treat shipping tolerance as a validated shelf life.
- Reconstitution
- bacteriostatic water
- Use the vial-specific protocol. Add gently and roll or swirl without shaking.
- Half-life
- less than 30 minutes
- rats and dogs after IV or IM dosing; parent peptide was undetectable by 4 hours
Basis: Vendor consensus. Sources: Frontiers/PMC BPC-157 animal pharmacokinetics, Palmetto BPC-157 storage protocol, American Peptides BPC-157 product storage
Vendor guidance calls for sealed BPC-157 powder at -20°C long term, with 2 to 8°C used only for short periods. After mixing with bacteriostatic water, the common vendor window is 28 to 30 days at 2 to 8°C. These are vendor conventions, not a published pharmaceutical expiry.
Keep the vial sealed, dry, dark, and protected from moisture. Arginate and acetate products are not interchangeable stability datasets, so product identity and third-party testing still matter.
A 2022 animal pharmacokinetic study found a parent-peptide half-life of less than 30 minutes in rats and dogs after IV or IM dosing. That contradicts the often repeated unsourced claim of a roughly 4-hour plasma half-life, and it does not establish stability in a vial.
Safety & cautions
In animal studies BPC-157 has looked strikingly low-toxicity, with no consistent serious adverse effects reported. But 'safe in rats' is not 'safe in humans,' and there is no long-term human safety data.
Because it promotes blood-vessel growth, there is a theoretical concern about its effect on tumors, though this has not been demonstrated. It is banned by WADA for athletes. Anyone considering it should understand it is unapproved, unregulated, and unstudied in humans at scale.
Watch BPC-157 prices
We'll email you when prices drop, a discount code changes, or new lab results come in for BPC-157. No spam — only real changes.
Frequently asked questions
Is BPC-157 FDA approved?
No. BPC-157 is not approved as a drug or supplement by the FDA or any major regulator. In 2023 the FDA flagged it as a substance that poses risks when compounded. It is sold only as a research material.
Is there real human evidence for BPC-157?
Very little. The overwhelming majority of studies are in cells and rodents. Human evidence is essentially limited to anecdote and a small number of early investigations — not the large controlled trials needed to prove it works or is safe.
What is the BPC-157 hamstring trial?
NCT07437547 is a ClinicalTrials.gov record describing a recruiting Phase 2 hamstring-strain study in 120 estimated adults. PeptidePub has not independently validated the sponsor, site, or recruitment activity. Hudson Biotech also registered one record labeled “Mock Study” and another using Lilly's SURMOUNT-1 title and acronym, so this record should not be treated as efficacy evidence. No results are posted.
What do people research BPC-157 for?
Most interest centers on tendon, ligament, muscle, and gut healing, based on the animal literature. These are research interests, not proven human uses.
Why do prices and quality vary so much?
Because it is an unregulated research chemical, there is no manufacturing standard. Purity, identity, and sterility differ between vendors — the reason independent third-party testing (COAs) is the single most important thing to check before buying.
Sources
- Chang et al. — BPC-157 and tendon fibroblast healing (J Appl Physiol)
- Sikiric et al. — BPC-157 review of cytoprotection & angiogenesis
- ClinicalTrials.gov - NCT07437547 BPC 157 for Acute Hamstring Muscle Strain Repair
- ClinicalTrials.gov - NCT07481734 Hudson Biotech Mock Study registry record
- ClinicalTrials.gov - NCT07481747 Hudson Biotech SURMOUNT-1 registry record
- FDA - July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting
- Pharmaceutical Executive - July 23 PCAC vote results for BPC-157 and TB-500
- CNBC - October 15, 2026 White House review of interim peptide access policy
- Reuters - HHS and FDA submit interim peptide compounding policy for White House review
- FDA — bulk drug substances nominated for compounding (Category 2 risk)
Last reviewed October 20, 2026. This guide is educational and research-focused, not medical advice. BPC-157 products referenced on PeptidePub are sold by third parties as materials for laboratory research use only, not for human or animal consumption.
GO DEEPER
This guide covers one compound. We wrote the book on all 45.
The Peptide Handbook takes everything we know from testing vendors for a living and turns it into five readable books: what each compound actually does, what the evidence really says, and the honest call when the answer is "skip this one." Plus the dosing tables, calendars, and trackers that make it usable.